Skip to Main Content

Paper Details

Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2).
1
2023
Anti-GM-CSF otilimab, Patients, antigranulocyte-macrophage colony-stimulating factor antibody, contRAst, contRAst 1, contRAst 2, methotrexate, otilimab, patients, rheumatoid arthritis, tofacitinib
Author NameAffiliation
Michael E WeinblattBrigham and Women's Hospital, Harvard University
  • 1 - 1

Datasets

Release 1.2